PT - JOURNAL ARTICLE AU - Honigberg, Michael C. AU - Economy, Katherine E. AU - Pabón, Maria A. AU - Wang, Xiaowen AU - Castro, Claire AU - Brown, Jenifer M. AU - Divakaran, Sanjay AU - Weber, Brittany N. AU - Barrett, Leanne AU - Perillo, Anna AU - Sun, Anina Y. AU - Antoine, Tajmara AU - Farrohi, Faranak AU - Docktor, Brenda AU - Lau, Emily S. AU - DeFaria Yeh, Doreen AU - Natarajan, Pradeep AU - Sarma, Amy A. AU - Weisbrod, Robert M. AU - Hamburg, Naomi M. AU - Ho, Jennifer E. AU - Roh, Jason D. AU - Wood, Malissa J. AU - Scott, Nandita S. AU - Di Carli, Marcelo F. TI - Coronary Microvascular Function Following Severe Preeclampsia AID - 10.1101/2024.03.04.24303728 DP - 2024 Jan 01 TA - medRxiv PG - 2024.03.04.24303728 4099 - http://medrxiv.org/content/early/2024/03/05/2024.03.04.24303728.short 4100 - http://medrxiv.org/content/early/2024/03/05/2024.03.04.24303728.full AB - Background Preeclampsia is a pregnancy-specific hypertensive disorder associated with an imbalance in circulating pro- and anti-angiogenic proteins. Preclinical evidence implicates microvascular dysfunction as a potential mediator of preeclampsia-associated cardiovascular risk.Methods Women with singleton pregnancies complicated by severe antepartum-onset preeclampsia and a comparator group with normotensive deliveries underwent cardiac positron emission tomography (PET) within 4 weeks of delivery. A control group of pre-menopausal, non-postpartum women was also included. Myocardial flow reserve (MFR), myocardial blood flow (MBF), and coronary vascular resistance (CVR) were compared across groups. Soluble fms-like tyrosine kinase receptor-1 (sFlt-1) and placental growth factor (PlGF) were measured at imaging.Results The primary cohort included 19 women with severe preeclampsia (imaged at a mean 16.0 days postpartum), 5 with normotensive pregnancy (mean 14.4 days postpartum), and 13 non-postpartum female controls. Preeclampsia was associated with lower MFR (β=-0.67 [95% CI −1.21 to −0.13]; P=0.016), lower stress MBF (β=-0.68 [95% CI, −1.07 to −0.29] mL/min/g; P=0.001), and higher stress CVR (β=+12.4 [95% CI 6.0 to 18.7] mmHg/mL/min/g; P=0.001) vs. non-postpartum controls. MFR and CVR after normotensive pregnancy were intermediate between preeclamptic and non-postpartum groups. Following preeclampsia, MFR was positively associated with time following delivery (P=0.008). The sFlt-1/PlGF ratio strongly correlated with rest MBF (r=0.71; P<0.001), independent of hemodynamics.Conclusions In this exploratory study, we observed reduced coronary microvascular function in the early postpartum period following severe preeclampsia, suggesting that systemic microvascular dysfunction in preeclampsia involves the coronary microcirculation. Further research is needed to establish interventions to mitigate risk of preeclampsia-associated cardiovascular disease.Competing Interest StatementDr. Honigberg reports consulting fees from CRISPR Therapeutics and Comanche Biopharma, advisory board service for Miga Health, and grant support from Genentech. Dr. Brown reports consulting fees from Bayer AG and AstraZeneca. Dr. Weber reports advisory board service for Novo Nordisk, Horizon Therapeutics, Kinsika Pharmaceuticals, and Aegpha. Dr. Lau reports previous advisory board service for Astellas Pharma. Dr. Natarajan reports research grants from Allelica, Apple, Amgen, Boston Scientific, Genentech / Roche, and Novartis, personal fees from Allelica, Apple, AstraZeneca, Blackstone Life Sciences, Foresite Labs, Genentech / Roche, GV, HeartFlow, Magnet Biomedicine, and Novartis, scientific advisory board membership of Esperion Therapeutics, Preciseli, and TenSixteen Bio, scientific co-founder of TenSixteen Bio, equity in Preciseli and TenSixteen Bio, and spousal employment at Vertex Pharmaceuticals, all unrelated to the present work. Dr. Hamburg reports consulting fees from Merck, Boston Scientific, and Novo Nordisk, all unrelated to the present work. Dr. Di Carli reports grant support from Gilead Sciences, in-kind research support from Amgen, and consulting fees from Sanofi, MedTrace Pharma, and Vale Health.Funding StatementThis work was supported by Massachusetts General Hospital Corrigan Women's Heart Health Program and the Brigham and Women's Hospital Cardiovascular Imaging Program. Dr. Honigberg is supported by the National Heart, Lung, and Blood Institute (NHLBI, K08HL166687) and the American Heart Association (940166, 979465). Dr. Wang is supported by the NHLBI (T32HL094301) and by the Connors Center for Women's Health and Gender Biology at Brigham and Women's Hospital. Dr. Brown is supported by the NHLBI (K23HL159279) and American Heart Association (852429). Dr. Weber is supported by the NHLBI (K23HL159276) and American Heart Association (851511). Dr. Lau is supported by the NHLBI (K23HL159243) and American Heart Association (853922). Dr. Natarajan is supported by grants from the NHLBI (R01HL142711, R01HL148050, R01HL148565) and Fondation Leducq (TNE-18CVD04). Dr. Hamburg is supported by the NHLBI (R01HL160003, R01HL168889) and the American Heart Association (20SRFRN35120118). Dr. Ho is supported by the NHLBI (K24HL153669, R01HL160003). Dr. Roh is supported by the NHLBI (R01HL170048), National Institute on Aging (K76AG04328), MGH Transformative Scholars Award, and the Fred and Ines Yeatts Fund for Innovative Research. Dr. Scott receives support from the NHLBI (REBIRTH trial, NCT05180773) and from the Heart Outcomes in Pregnancy Expectations (HOPE) registry. Dr. Di Carli is supported by the NIH (R01HL162960, R01EB034586).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Mass General Brigham IRB gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.